Complexa, Inc. Completes $13 Million Series B Financing to Further Advance Clinical Development of CXA-10

  Complexa, Inc. Completes $13 Million Series B Financing to Further Advance
  Clinical Development of CXA-10

Business Wire

PITTSBURGH -- June 4, 2014

Complexa, Inc., a clinical-stage platform anti-inflammatory and fibrotic
disease-focused biopharmaceutical company, announced today that it has
completed a $13 million dollar Series B financing. The company will use funds
raised to further advance clinical development of two formulations of its lead
compound CXA-10. The first is an intravenous formulation which is currently in
Phase I clinical trials for a form of acute kidney disease and the second is
an oral formulation for a form of chronic kidney disease for which an IND will
be filed later this year. JAFCO Life Science Investment, a part of JAFCO Co.,
Ltd. (“JAFCO”) led the financing round with significant participation from
existing investors.

Complexa board members and JAFCO representatives Kenji Harada, Ph.D., and
Hironori Hozoji jointly said, “We see very broad potential for Complexa’s
technology in fighting inflammatory and fibrotic-based diseases and look
forward to seeing the data from Complexa’s advancing CXA-10 clinical programs.
There is great interest from large pharmaceutical companies in this type of
novel human pathway signaling technology and a large underserved patient
population facing the life-threatening inflammatory-based diseases that
Complexa is studying.”

Company President and CEO Josh Tarnoff added, “We’re delighted to have JAFCO
join the Complexa investor base. The JAFCO team has a long history of being
very supportive of its funded companies. They bring highly valued
contributions to Complexa.”

Earlier this month, Complexa announced that it began Phase I trials for the
treatment of acute kidney injury related to the administration of contrast
imaging agents in high-risk patients, CXA-10’s proof of concept indication.
This Phase I trial is designed to assess CXA-10’s safety and pharmacokinetics.
Through the use of various biomarkers, the study will also demonstrate
CXA-10’s mechanism of action and document target organ engagement that will
further illuminate its regulation of critical inflammatory pathways.

CXA-10 and related drug candidates in Complexa’s portfolio utilize the body’s
own endogenous signaling pathways to promote defense and repair responses,
which can be applied to a number of underserved, life-threatening
inflammatory-based diseases. Complexa continues its work on oral chronic
treatments, and development programs in other inflammatory, neurodegenerative
and fibrotic-related therapeutic categories are also under active evaluation.

About Complexa

Complexa, Inc. is a clinical stage platform biopharmaceutical company
researching and developing endogenous human cell signaling technologies
targeting an array of prevalent inflammatory, fibrotic, and CNS diseases. The
company’s proprietary technology involves the synthesis and therapeutic
applications of endogenous nitro-fatty acids (NFAs) and additional
structure/function-related mediators that are designed to treat various
diseases. NFAs are cell signaling agents that regulate major inflammatory
signaling pathways (e.g., Nrf2, NFkB and HSF). Capitalizing on their
identification and synthesis of these endogenous signaling mediators,
Complexa’s technologies act to amplify the existing anti-inflammatory and
metabolic signaling mechanisms that promote the resolution and repair of acute
and chronic tissue injury and disease.

This press release contains “forward-looking statements” concerning the
development of Complexa's products, the potential benefits and attributes of
such products, and Complexa's expectations regarding its prospects.
Forward-looking statements are subject to risks, assumptions and uncertainties
that could cause actual future events or results to differ materially from
such statements. These statements are made as of the date of this press
release. Actual results may vary. Complexa undertakes no obligation to update
any forward-looking statements for any reason.

For further information please visit or contact the company
at 412.727.8727.


Sam Brown Inc.
Mike Beyer, 773-463-4211
Press spacebar to pause and continue. Press esc to stop.